CLINICAL TRIALS PROFILE FOR OMEPRAZOLE MAGNESIUM
✉ Email this page to a colleague
All Clinical Trials for OMEPRAZOLE MAGNESIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00206440 ↗ | Nexium Study To Suppress Nausea During Chemotherapy | Terminated | AstraZeneca | Phase 3 | 2005-08-01 | This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy. |
| NCT00206440 ↗ | Nexium Study To Suppress Nausea During Chemotherapy | Terminated | Baylor Breast Care Center | Phase 3 | 2005-08-01 | This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy. |
| NCT00674115 ↗ | A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED) | Completed | Bausch Health Americas, Inc. | Phase 3 | 2008-04-01 | Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. The other 30 participants will receive a single administration of sodium bicarbonate. |
| NCT00674115 ↗ | A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED) | Completed | Valeant Pharmaceuticals International, Inc. | Phase 3 | 2008-04-01 | Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. The other 30 participants will receive a single administration of sodium bicarbonate. |
| NCT00674115 ↗ | A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED) | Completed | Bayer | Phase 3 | 2008-04-01 | Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. The other 30 participants will receive a single administration of sodium bicarbonate. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OMEPRAZOLE MAGNESIUM
Condition Name
Clinical Trial Locations for OMEPRAZOLE MAGNESIUM
Trials by Country
Clinical Trial Progress for OMEPRAZOLE MAGNESIUM
Clinical Trial Phase
Clinical Trial Sponsors for OMEPRAZOLE MAGNESIUM
Sponsor Name
